---
document_datetime: 2025-12-02 05:35:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/galafold.html
document_name: galafold.html
version: success
processing_time: 0.1066528
conversion_datetime: 2025-12-25 03:57:56.738429
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Galafold

[RSS](/en/individual-human-medicine.xml/66741)

##### Authorised

This medicine is authorised for use in the European Union

migalastat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Galafold](#news-on)
- [More information on Galafold](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Galafold. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Galafold.

For practical information about using Galafold, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Galafold and what is it used for?

Galafold is a medicine used to treat patients aged 12 years and above who have Fabry disease. This is a rare inherited disorder where patients have various mutations (changes) in the gene responsible for the production of an enzyme called alpha-galactosidase. This enzyme normally breaks down a fatty substance called globotriaosylceramide (GL-3). As a result of the mutations, the enzyme does not work properly and cannot break down GL-3. This leads to a build up of GL-3 in various cells in the body, including in the heart and kidneys.

Fabry disease is rare, and Galafold was designated an 'orphan medicine' (a medicine used in rare diseases) on 22 May 2006.

Galafold contains the active substance migalastat.

## How is Galafold used?

Galafold can only be obtained with a prescription and treatment should only be started and supervised by a doctor who is experienced in the diagnosis and treatment of Fabry disease.

Galafold is available as capsules. The recommended dose of Galafold is one capsule every other day. Patients should not consume any food at least 2 hours before and 2 hours after taking Galafold to allow full absorption.

Galafold is only for use in patients with certain mutations in the alpha-galactosidase A gene. For more information about using Galafold, see the package leaflet or contact your doctor or pharmacist.

## How does Galafold work?

The active substance in Galafold, migalastat, attaches to certain unstable forms of alpha-galactosidase A, stabilising the enzyme. This allows the enzyme to be transported into areas of the cell where it can break down GL-3.

## What benefits of Galafold have been shown in studies?

Galafold has been investigated in two main studies involving a total of 127 patients aged over 16 years with Fabry disease.

The first study, which compared Galafold with placebo (a dummy treatment) in 67 patients, looked at the proportion of patients who responded to treatment (defined as a reduction of at least 50% in GL-3 deposits in the kidneys). Overall, Galafold was not found to be more effective than placebo at reducing GL-3 deposits; however, additional analyses including only patients with those genetic mutations that can be treated with Galafold showed that patients responded better to Galafold than to placebo after 6 months of treatment.

The second study, in 60 patients, compared Galafold with the medicines agalsidase alfa or agalsidase beta, two treatments that replace the missing enzyme. The main measure of effectiveness was the change in patients' kidney function after 18 months of treatment. In this study, Galafold was found to be as effective as enzyme replacement in stabilising patients' kidney function.

The company also provided results of a study that showed that Galafold produces the same levels of the active substance in the body and has the same effect in adolescents aged 12 up to and including 15 years old as in adults and young people aged 16 and above.

## What are the risks associated with Galafold?

The most common side effect with Galafold (which may affect around 1 in 10 people) is headache.

For the full list of all side effects and restrictions with Galafold, see the package leaflet.

## Why is Galafold authorised in the EU?

The European Medicines Agency decided that Galafold's benefits are greater than its risks and it can be authorised for use in the EU. The Agency noted that Galafold was studied in a limited number of patients, however the available evidence is considered sufficient for such a rare disease. The Agency also noted that Galafold is taken by mouth and this could be an advantage compared with other authorised treatments such as enzyme replacement which are given by infusion (drip) into a vein. Regarding safety, Galafold was well-tolerated.

## What measures are being taken to ensure the safe and effective use of Galafold?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Galafold have been included in the summary of product characteristics and the package leaflet.

## Other information about Galafold

Galafold received a marketing authorisation valid throughout the EU on 26 May 2016.

Galafold : EPAR - Summary for the public

English (EN) (118.5 KB - PDF)

**First published:** 09/06/2016

**Last updated:** 27/08/2021

[View](/en/documents/overview/galafold-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-231)

български (BG) (142.9 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/bg/documents/overview/galafold-epar-summary-public_bg.pdf)

español (ES) (118.96 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/es/documents/overview/galafold-epar-summary-public_es.pdf)

čeština (CS) (139.74 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/cs/documents/overview/galafold-epar-summary-public_cs.pdf)

dansk (DA) (117 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/da/documents/overview/galafold-epar-summary-public_da.pdf)

Deutsch (DE) (133.34 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/de/documents/overview/galafold-epar-summary-public_de.pdf)

eesti keel (ET) (105.93 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/et/documents/overview/galafold-epar-summary-public_et.pdf)

ελληνικά (EL) (141.07 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/el/documents/overview/galafold-epar-summary-public_el.pdf)

français (FR) (119.91 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/fr/documents/overview/galafold-epar-summary-public_fr.pdf)

hrvatski (HR) (139.85 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/hr/documents/overview/galafold-epar-summary-public_hr.pdf)

italiano (IT) (146.36 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/it/documents/overview/galafold-epar-summary-public_it.pdf)

latviešu valoda (LV) (154.14 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/lv/documents/overview/galafold-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (139.21 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/lt/documents/overview/galafold-epar-summary-public_lt.pdf)

magyar (HU) (139.73 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/hu/documents/overview/galafold-epar-summary-public_hu.pdf)

Malti (MT) (139.94 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/mt/documents/overview/galafold-epar-summary-public_mt.pdf)

Nederlands (NL) (118.69 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/nl/documents/overview/galafold-epar-summary-public_nl.pdf)

polski (PL) (143.38 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/pl/documents/overview/galafold-epar-summary-public_pl.pdf)

português (PT) (119.46 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/pt/documents/overview/galafold-epar-summary-public_pt.pdf)

română (RO) (137.89 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/ro/documents/overview/galafold-epar-summary-public_ro.pdf)

slovenčina (SK) (140.37 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/sk/documents/overview/galafold-epar-summary-public_sk.pdf)

slovenščina (SL) (137.25 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/sl/documents/overview/galafold-epar-summary-public_sl.pdf)

Suomi (FI) (115.34 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/fi/documents/overview/galafold-epar-summary-public_fi.pdf)

svenska (SV) (116.35 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

27/08/2021

[View](/sv/documents/overview/galafold-epar-summary-public_sv.pdf)

## Product information

Galafold : EPAR - Product Information

English (EN) (1.58 MB - PDF)

**First published:** 09/06/2016

**Last updated:** 25/08/2025

[View](/en/documents/product-information/galafold-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-492)

български (BG) (1.95 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/bg/documents/product-information/galafold-epar-product-information_bg.pdf)

español (ES) (1.55 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/es/documents/product-information/galafold-epar-product-information_es.pdf)

čeština (CS) (1.65 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/cs/documents/product-information/galafold-epar-product-information_cs.pdf)

dansk (DA) (1.59 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/da/documents/product-information/galafold-epar-product-information_da.pdf)

Deutsch (DE) (1.71 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/de/documents/product-information/galafold-epar-product-information_de.pdf)

eesti keel (ET) (1.58 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/et/documents/product-information/galafold-epar-product-information_et.pdf)

ελληνικά (EL) (1.52 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/el/documents/product-information/galafold-epar-product-information_el.pdf)

français (FR) (1.74 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/fr/documents/product-information/galafold-epar-product-information_fr.pdf)

hrvatski (HR) (1.6 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/hr/documents/product-information/galafold-epar-product-information_hr.pdf)

íslenska (IS) (1.8 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/is/documents/product-information/galafold-epar-product-information_is.pdf)

italiano (IT) (1.67 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/it/documents/product-information/galafold-epar-product-information_it.pdf)

latviešu valoda (LV) (1.56 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/lv/documents/product-information/galafold-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.72 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/lt/documents/product-information/galafold-epar-product-information_lt.pdf)

magyar (HU) (1.79 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/hu/documents/product-information/galafold-epar-product-information_hu.pdf)

Malti (MT) (1.78 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/mt/documents/product-information/galafold-epar-product-information_mt.pdf)

Nederlands (NL) (1.61 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/nl/documents/product-information/galafold-epar-product-information_nl.pdf)

norsk (NO) (1.88 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/no/documents/product-information/galafold-epar-product-information_no.pdf)

polski (PL) (1.55 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/pl/documents/product-information/galafold-epar-product-information_pl.pdf)

português (PT) (1.75 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/pt/documents/product-information/galafold-epar-product-information_pt.pdf)

română (RO) (1.73 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/ro/documents/product-information/galafold-epar-product-information_ro.pdf)

slovenčina (SK) (1.57 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/sk/documents/product-information/galafold-epar-product-information_sk.pdf)

slovenščina (SL) (1.54 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/sl/documents/product-information/galafold-epar-product-information_sl.pdf)

Suomi (FI) (1.66 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/fi/documents/product-information/galafold-epar-product-information_fi.pdf)

svenska (SV) (1.63 MB - PDF)

**First published:**

09/06/2016

**Last updated:**

25/08/2025

[View](/sv/documents/product-information/galafold-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000285583 22/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Galafold : EPAR - All Authorised presentations

English (EN) (15.02 KB - PDF)

**First published:** 09/06/2016

**Last updated:** 09/06/2016

[View](/en/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-315)

български (BG) (40.17 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/bg/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.94 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/es/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.34 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/cs/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.68 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/da/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/de/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.78 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/et/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.63 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/el/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_el.pdf)

français (FR) (17.81 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/fr/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (23.77 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/hr/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.96 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/is/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.77 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/it/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.07 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/lv/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.55 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/lt/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.9 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/hu/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.18 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/mt/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.73 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/nl/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (14.89 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/no/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.02 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/pl/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.72 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/pt/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_pt.pdf)

română (RO) (33.07 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/ro/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.67 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/sk/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.17 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/sl/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.72 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/fi/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.77 KB - PDF)

**First published:**

09/06/2016

**Last updated:**

09/06/2016

[View](/sv/documents/all-authorised-presentations/galafold-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Galafold Active substance migalastat hydrochloride International non-proprietary name (INN) or common name migalastat Therapeutic area (MeSH) Fabry Disease Anatomical therapeutic chemical (ATC) code A16AX

### Pharmacotherapeutic group

migalastat

### Therapeutic indication

Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (?-galactosidase A deficiency) and who have an amenable mutation.

## Authorisation details

EMA product number EMEA/H/C/004059

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Amicus Therapeutics Europe Limited

Block 1, Blanchardstown Corporate Park Ballycoolin Road Blanchardstown Dublin 15 D15 AKK1 Ireland

Opinion adopted 30/03/2016 Marketing authorisation issued 25/05/2016 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Galafold : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.36 KB - PDF)

**First published:** 25/08/2025

[View](/en/documents/procedural-steps-after/galafold-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Galafold : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (215.07 KB - PDF)

**First published:** 28/10/2016

**Last updated:** 25/08/2025

[View](/en/documents/procedural-steps-after/galafold-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Galafold-H-C-004059-II-0034 : EPAR - Assessment report variation

Adopted

Reference Number: EMA/123203/2022

English (EN) (582.91 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/variation-report/galafold-h-c-004059-ii-0034-epar-assessment-report-variation_en.pdf)

Galafold-H-C-004059-II-0029 : EPAR - Assessment report variation

Adopted

Reference Number: EMA/CHMP/412211/2021

English (EN) (1.26 MB - PDF)

**First published:** 27/08/2021

[View](/en/documents/variation-report/galafold-h-c-004059-ii-0029-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Galafold (II-29)

Adopted

Reference Number: EMA/CHMP/302791/2021

English (EN) (138.18 KB - PDF)

**First published:** 25/06/2021

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-galafold-ii-29_en.pdf)

## Initial marketing authorisation documents

Galafold : EPAR - Public assessment report

Adopted

Reference Number: EMA/272226/2016

English (EN) (1.62 MB - PDF)

**First published:** 09/06/2016

**Last updated:** 09/06/2016

[View](/en/documents/assessment-report/galafold-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Galafold

Adopted

Reference Number: EMA/CHMP/220589/2016

English (EN) (82.95 KB - PDF)

**First published:** 01/04/2016

**Last updated:** 01/04/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-galafold_en.pdf)

#### News on Galafold

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021) 25/06/2021

[First oral treatment for Fabry disease recommended for approval in the EU](/en/news/first-oral-treatment-fabry-disease-recommended-approval-eu) 01/04/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 29 March - 1 April 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-29-march-1-april-2016) 01/04/2016

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0040590000) (initial marketing authorisation)

#### More information on Galafold

- [EU/3/06/368 - orphan designation for treatment of Fabry disease](/en/medicines/human/orphan-designations/eu-3-06-368)
- [EMEA-001194-PIP01-11-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001194-pip01-11-m06)
- [A Prospective, Observational Registry of Patients with Fabry Disease (AT1001-030) - post-authorisation study](https://catalogues.ema.europa.eu/study/35885)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/08/2025

## Share this page

[Back to top](#main-content)